Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard Heyman sold 1,230 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $26.75, for a total transaction of $32,902.50. Following the transaction, the director directly owned 23,877 shares of the company’s stock, valued at $638,709.75. The trade was a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Enliven Therapeutics Stock Performance

Shares of ELVN traded down $0.17 during midday trading on Thursday, hitting $27.03. 1,466,778 shares of the company traded hands, compared to its average volume of 1,935,634. The firm has a 50 day moving average of $20.22 and a 200-day moving average of $20.27. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $29.98. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of -14.69 and a beta of 0.41.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. Sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ELVN has been the topic of several research reports. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Enliven Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Institutional Investors Weigh In On Enliven Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Affinity Asset Advisors LLC purchased a new stake in Enliven Therapeutics during the second quarter valued at approximately $8,024,000. Geode Capital Management LLC grew its holdings in Enliven Therapeutics by 7.8% in the second quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock worth $17,711,000 after purchasing an additional 63,580 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Enliven Therapeutics by 2,029.3% during the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after purchasing an additional 410,034 shares in the last quarter. KLP Kapitalforvaltning AS lifted its holdings in shares of Enliven Therapeutics by 58.1% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after purchasing an additional 2,500 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Enliven Therapeutics by 177.4% in the 2nd quarter. SG Americas Securities LLC now owns 36,373 shares of the company’s stock worth $730,000 after purchasing an additional 23,261 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.